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ABSTRACT
Hidradenitis suppurativa (HS) is a chronic,
recurrent skin inflammatory disease associated
with a variety of comorbidities, like reduced
quality of life, metabolic syndrome, sexual
dysfunction, working disability, axial spondy-
loarthritis, inflammatory bowel disease,
depression, and anxiety. Like psoriasis, HS
patients have been found to have higher risk of
cardiovascular death and suicide risk. Clinicians
should be informed about these comorbidities
so that appropriate screening is implemented.
All this evidence suggests that for such a
chronic, multi-comorbid disease, the use of
validated outcomes to assess severity and effect
of treatment, along with the use of clinically
important patient reported outcomes, is essen-
tial. The potential of available treatments to
negatively and positively affect these comor-
bidities should also be taken into account when
designing treatment strategies. This review
provides an outline of important HS comor-
bidities with emphasis on possible implications
for daily clinical practice.
Keywords: Clinical significance; Comorbidi-
ties; Depression; Hidradenitis suppurativa;
Inflammatory bowel disease; Metabolic
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Key Summary Points
Hidradenitis suppurativa is a chronic,
recurrent skin inflammatory disease
associated with significant psychological
burden, like reduced quality of life,
depression, anxiety, and sexual
dysfunction.
Important comorbidities include working
disability, metabolic syndrome,
inflammatory bowel disease and axial
spondyloarthritis.
Hidradenitis suppurativa patients are at
higher risk of cardiovascular death and
suicide risk.
Appropriate screening in daily clinical
practice should be implemented for early
identification and evidence based
treatment.
The use of validated outcomes for
assessment of disease severity and
treatment effect, along with the use of
important patient reported outcomes, is
essential.
INTRODUCTION
Hidradenitis suppurativa (HS), or acne inversa,
is a chronic inflammatory skin disease charac-
terized by recurrent inflammation and deep-
seated lesions in apocrine gland-bearing intert-
riginous areas of the body that can be poten-
tially scarring and debilitating [1–3]. Prevalence
of HS varies widely from 0.03 to 8%, depending
on the setting and methodology used [4].
Patients often experience long delays before an
HS diagnosis is established [5]. HS typically
develops between puberty and the age of
40 years, thus impacts individuals at working
age [2]. It is known to have substantial impact
on several general health-related and skin-
specific quality of life domains [6, 7], is associ-
ated with a significant comorbidity burden [3]
and overall mortality, and is becoming more
widely recognized as an inflammatory disease
with a number of systemic implications, like
psoriasis.
In a recent global patient survey it became
evident that patients reported a high frequency
of comorbidities and that they were dissatisfied
with medical or procedural treatments in 45.9%
and 34.5%, respectively [8]. For such a chronic,
debilitating inflammatory skin disease it is
important that clinicians are well informed on
possible comorbidities that can have a signifi-
cant impact. The aim of the review is to present
an up-to-date overview of HS comorbidities,
discuss their clinical significance and how they
can be addressed meaningfully, and shape daily
treatment decisions (Table 1). This article is
based on previously conducted studies and does
not contain any studies with humanparticipants
or animals performed by any of the authors.
INCREASED CARDIOVASCULAR
(CV) DISEASE RISK
A meta-analysis of observational studies
including 6174 HS patients and 24,993 controls
detected significant association of HS with
obesity, central obesity, active smoking, history
of smoking, hypertriglyceridemia, low HDL,
diabetes, and metabolic syndrome [9]. These
associations were significant both in population
HS patients and hospital HS groups, with hos-
pital HS groups having uniformly higher odds
ratios than the population HS groups. CV risk
factors appear at a significantly higher rate in
HS patients compared to controls. Increased CV
risk is manifest even in patients identified in
population samples. Obesity is also a well-
established independent risk factor for HS with
improvements in disease severity demonstrated
after weight loss, like lower HS prevalence and
severity, better long-term prognosis, sponta-
neous resolution of HS, flare reduction and
reduced recurrence after CO2 laser surgery
[10–13].
In a cross-sectional study with 68 HS patients
and 136 age- and sex-matched healthy control
subjects, HS was significantly related to pres-
ence of carotid plaques and increased frequency
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Table 1. Important HS comorbidities and their implications for daily clinical practice
Comorbidities Clinical significance
Association with cardiovascular disease risk factors: obesity,
smoking, hypertriglyceridemia, low HDL, diabetes,
metabolic syndrome [9]
Increased frequency of subclinical atherosclerosis [14]
Increased risk of adverse cardiovascular outcomes [16]
Need for screening for modifiable cardiovascular risks
Avoid treatments with potential negative impact on
cardiovascular disease risk factors, e.g., acitretin
Implement weight loss strategies
Association with slower income growth, higher risk of
leaving the workforce, more total work loss days, higher
annual total indirect costs and lower annual income
[17–20]
HS patients have unmet disease management needs
Major surgery in selected cases may improve activity and
overall work impairment [21]
Adalimumab significantly improved total work impairment
compared to placebo [22]
Axial spondyloarthritis
Association with increased risk of spondyloarthritis [23]
In axial spondyloarthritis patients disease activity score is
independently associated with presence of HS [24]
HS patients with osteoarticular symptoms (low back pain,
dactylitis) should be monitored for spondyloarthritis
Axial spondyloarthritis patients with HS may have higher
disease activity
Significant associations of HS with CD and ulcerative colitis
[25]
HS patients are at risk for CD [26]
Consultation with gastroenterologists if HS patients have
recurrent abdominal pain, chronic diarrhea, bloody stool,
or body weight loss
Reduced quality of life, social isolation [28, 29]
Sexual dysfunction [31]
Depression, anxiety, schizophrenia [29, 34, 35]
Increased antidepressant drug use [36]
Increased suicide risk [36]
Development of strategies to recognize and treat those
psychiatric comorbidities in patients with HS is warranted
Syndromic HS: [36]
PAPA: pyoderma gangrenosum, acne, pyogenic arthritis
PASH: pyoderma gangrenosum, acne, and HS
PAPASH: pyoderma gangrenosum, acne, pyogenic arthritis,
and HS
Lack of response to standard treatment modalities
Early identification is critical in order to optimize
management
Other
Long-term opioid use [38]
Psoriasis [39], pyoderma gangrenosum [40]
Alopecia areata [40], vitiligo [41]
rheumatoid arthritis [40], non melanoma skin cancer [42]
Older patients, smokers, and patients with depression may
benefit from periodic screening for long-term opioid use
HS hidradenitis suppurativa, CD Crohn’s disease
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of subclinical atherosclerosis [14]. In a cross-
sectional Danish general population study,
mean resting heart rate in patients with severe
HS was significantly higher compared with
controls [15]. A population-based cohort study
using individual-level linkage of nationwide
administrative registers indicated that HS was
associated with a significantly increased risk of
adverse CV outcomes and all-cause mortality
independent of measured confounders [16].
Notably, the risk of CV death was 58% higher in
patients with HS than in patients with severe
psoriasis.
These results emphasize the need for
screening of HS patients for modifiable CV risk
factors and consideration of them when decid-
ing treatment options. For example, acitretin
would be better avoided as a treatment for an
HS patient with dislipidemia, since an abnormal
lipid profile is a well-known potential side
effect. Weight gain is a usual side effect of hor-
monal treatment (ethinyloestradiol and cypro-
terone acetate), especially with long-term use.
Pre-treatment screening should be performed
where necessary. Furthermore, weight reduc-
tion strategies appear to be beneficial and
should be implemented.
WORKING DISABILITY
HS has been demonstrated to have a significant
impact on patients’ work productivity and
negatively affect opportunities for career
advancement. In a Polish survey of employed
patients with HS, 58% reported that the disease
caused a work absence with a mean 33.6 days
off work annually, 10% reported that they lost
their job because of HS and 23% believed that
HS interfered with promotion [17]. In addition,
patients with HS experience a substantial eco-
nomic burden, with the total direct healthcare
costs of patients with HS estimated to be $6783
higher compared to those of controls over a
3-year period [18]. Higher total work produc-
tivity impairment scores compared to psoriasis
were reported for HS [19]. In a US claims data-
base analysis, newly diagnosed HS patients had
significantly slower income growth and higher
risk of leaving the workforce compared with
controls. General HS patients had more total
work loss days, higher annual total indirect
costs, and lower annual income compared with
controls [20].
This evidence clearly indicates that HS
patients have unmet disease management needs
with respect to working disability. A single
center prospective survey study conducted
among 40 patients undergoing major surgery
suggested that, after major surgery activity,
overall work impairment showed considerable
improvement [21]. Individual patient data from
two phase 3, randomized, double-blinded stud-
ies, PIONEER I and II, and their open-label
extension (OLE) trial were used to compare
patients with moderate to severe HS treated
with adalimumab or placebo [22]. Patients with
HS receiving adalimumab experienced signifi-
cantly lower cumulative indirect costs and sig-
nificant improvement in total work impairment
compared to placebo [22].
AXIAL SPONDYLOARTHRITIS
A single center cross-sectional study showed
that HS was significantly associated with an
increased risk of spondyloarthritis, indepen-
dently of age and sex [23]. A cross-sectional
study using a cohort of axial spondyloarthritis
patients identified that HS was more prevalent
that in the general population and that a higher
score on axial spondyloarthritis disease activity
score was independently associated with HS
[24].
Patients with HS presenting osteoarticular
symptoms, especially low back pain or dactyli-
tis, should be monitored for spondyloarthritis.
Furthermore, axial spondyloarthritis patients
with HS may have higher disease activity.
INFLAMMATORY BOWEL DISEASE
A recently published meta-analysis of observa-
tional studies clearly showed significant associ-
ations of HS with Crohn’s disease (CD) and
ulcerative colitis (UC) [25]. Cross-sectional
analysis of data from 51,340 patients with HS,
identified using electronic health records data,
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suggested that HS patients are at risk for CD and
that prevalence of CD was greatest among
patients with HS who were white, aged
45–64 years, non-obese and tobacco smokers
[26]. High HS prevalence has been detected in
patients with perianal fistula [27].
In patients with chronic perianal and per-
ineal HS, and in particular in the presence of
fistulas, the possibility of CD should be con-
sidered. Consultation with gastroenterologists
should be sought when patients with HS pre-
sent with recurrent abdominal pain, chronic
diarrhea, bloody stools, and body weight loss.
Early detection of the coexistence can lead to
appropriate anti-inflammatory treatment to
reduce symptoms and disease progression.
PSYCHOLOGICAL COMORBIDITY
Psychological comorbidities are well established
and proven in HS patients. It was suggested that
more than 50% of HS patients experience a very
or extremely large effect of HS on quality of life,
as measured by the Dermatology Life Quality
Index (DLQI) [28]. Using EuroQoL-5D and DLQI
scores it was found that HS is in the top five skin
diseases with the most negatively affected
quality of life and that predictive factors were
young age at onset and more lesions per month
[29]. DLQI was significantly worse in females
compared to males. Quality of life in HS
patients was found to be more negatively
impacted than in psoriasis, acne, stroke, or
heart transplant candidates [28].
It was found that HS has a great emotional
impact on patients and promotes isolation due
to fear of stigmatization [30]. Body image dis-
satisfaction may result in feelings of shame,
embarrassment, and anxiety and cause lack of
self-confidence, depression, and social isolation.
Shame and irritation are frequent and relate to
smell, scars, itching, and pain [30, 31].
Significant impairment of sexual health has
also been clearly indicated in HS patients
compared with age-, sex-, and BMI-matched
controls, with women affected more than men
[28]. Sexual health was impacted in HS due to
inconvenience caused by skin inflammation,
physical appearance, diminished sexual desire,
fear of passing HS on to children and dimin-
ished desire of partner [31]. Risk factors for
sexual dysfunction for women were education
status, disease activity, pain and odor, and lack
of a stable relationship; and for men the risk
factors were increasing age, active genital
lesion and number of active areas [32, 33].
These results reinforce the need to take sexual
health into account when assessing disease
severity, response to treatment, and patient
goals of care.
A recent meta-analysis of the literature sug-
gested that depression and anxiety were very
common comorbid conditions in HS patients.
Depression was found to be correlated with
disease activity and an association between
inflammation (CRP levels) and depression has
also been identified [29, 34]. Recent evidence
from a nationwide population-based study
suggested that HS was associated with
schizophrenia, after adjusting for demographic
factors and smoking status [35].
Taking into account all the abovementioned
evidence, it is no surprise that data from a cross-
sectional and cohort study, using Danish
national registries, found that patients with HS
compared with the general population had an
increased risk of antidepressant drug use, com-
pleted suicides and suicidal behavior, and that
this increased risk of completed suicide
remained, after adjustment for confounding
factors [36].
SYNDROMIC HS
Syndromic HS exists as well. Autoinflammatory
syndromes associated with hidradenitis suppu-
rativa (HS) and/or acne are rare but potentially
debilitating disorders. Several clinically differ-
ent syndromes exist including pyoderma gan-
grenosum, acne, and pyogenic arthritis (PAPA),
pyoderma gangrenosum, acne, and hidradenitis
suppurativa (PASH), pyoderma gangrenosum,
acne, pyogenic arthritis, and hidradenitis sup-
purativa (PAPASH), psoriatic arthritis, pyo-
derma gangrenosum, acne, and hidradenitis
suppurativa (PsAPASH) and pyoderma gan-
grenosum, acne and ulcerative colitis (PAC)
[37].
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Important features in these syndromes are
painful arthritis, skin lesions (HS, acne and
pyoderma gangrenosum) and recurrent epi-
sodes of fever. Treatment can be challenging
due to lack of response to standard treatment
modalities. Early identification is critical in
order to optimize management.
OTHER COMORBIDITIES
A retrospective cohort study showed that HS
patients were at higher risk for long-term opioid
use [38]. Older patients, smokers, and patients
with depression were at higher risk for opioid
abuse. Evidence suggests that this subgroup of
patients may benefit from periodic screening for
long-term opioid use.
Association with psoriasis [39], alopecia
areata [40], vitiligo [41], pyoderma gangreno-
sum, rheumatoid arthritis, and non-melanoma
skin cancer [42] have also been suggested as
comorbid diseases.
DISCUSSION
The abovementioned evidence clearly indicates
that HS is a multifaceted disease with many
different comorbidities that, if not identified
early and treated properly, can result in a sig-
nificant burden for HS patients and society. In
order to cope with such a disease it is of high
importance to use validated outcomes to assess
the severity of the disease and treatment
effect.
IHS4 is a validated tool to dynamically assess
HS severity and can be used both in real life and
in a clinical trials setting. The IHS4 score is
calculated by the number of nodules (multi-
plied by 1) plus the number of abscesses (mul-
tiplied by 2) plus the number of draining
tunnels (multiplied by 4). A total score of 3 or
less signifies mild, 4–10 signifies moderate, and
11 or higher signifies severe disease. This cor-
relates well with the Hurley classification,
Expert Opinion, Physician’s Global Assessment,
Modified Sartorius score, and DLQI [43].
HiSCR (hidradenitis suppurativa clinical
response) is defined as C 50% reduction in
inflammatory nodule and abscess count and no
increase in number of abscesses or draining fis-
tulas compared with baseline [44]. The use of
HiSCR is supported by good-quality validation
studies, and is recommended to be used as a
dichotomous outcome measure to assess the
effects of anti-inflammatory treatment [44]. A
post hoc analysis of integrated data from two
phase 3 clinical trials (PIONEER I and II)
revealed that more HiSCR responders than non-
responders experienced clinically meaningful
improvement in the Dermatology Life Quality
Index, Pain Numeric Rating Scale, HS quality of
life, work-related performance, and non-work-
related performance. Clinically meaningful
outcomes in HS are more likely to be attained in
patients achieving HiSCR-level improvement.
Patient-reported outcome measures [e.g.,
DLQI, Numerical Rating Scale (NRS)] should be
included in the overall assessment of the HS
patient as they may offer important insight on
functioning, quality of life, and symptoms (e.g.,
pain and itching), especially when the mini-
mum clinically important differences for such
outcomes is used, like at least a four-unit
decrease in DLQI score and C 30% reduction in
NRS pain score.
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